Flupentixol dihydrochloride in daily doses of up to 3 mg possesses antidepressant, anxiolytic and activating properties which have been shown in many controlled, clinical trials. Its effect can be seen promptly ie, during the 1st week of treatment and also ceases soon after discontinuation.
Pharmacokinetics: The bioavailability after oral administration of flupentixol is about 40%. Maximum serum concentration is reached in 3-6 hrs. Flupentixol in small amounts crosses the placental barrier and is excreted in small amounts into the breast milk. The metabolites are devoid of psychopharmacological activity. The excretion proceeds mainly with feces but also to some degree with the urine. The biological half-life is about 35 hrs.
Depression involving anxiety, asthenia and lack of initiative. Chronic neuroses with anxiety, depression and inactivity. Psychosomatic disorders with asthenic reactions. Acute and situational anxiety and tension states in which a sedative/hypnotic effect is not required and especially when the patient is considered in danger of abusing minor tranquilizers.
Initially, 0.5 mg twice daily. Later the dose may be adjusted within the range of 0.5-3 mg daily.
Patients often respond to Fluanxol (Low Dosage) within 2 or 3 days. If no effect has been observed within 1 week of maximum dosage (3 mg daily) the drug should be withdrawn.
Treatment is symptomatic and supportive. Gastric lavage should be carried out immediately and activated charcoal may be administered. Measures aimed at supporting the respiratory and cardiovascular systems should be instituted; epinephrine must not be used for such patients.
Extremely excitable and overactive patients. Acute barbiturate, alcohol and opiate poisoning. Like other psychotropics, Fluanxol (Low Dosage) should preferably not be given during pregnancy. Comatose states, bone marrow depression.
Fluanxol (Low Dosage) should be used with caution in patients with severe hepatic or renal disease. If previously the patient has been treated with tranquilizers with a sedative effect, these should be withdrawn gradually.
Like other psychotropics, Fluanxol (Low Dosage) should preferably not be given during pregnancy.
Occasional: Restlessness and/or insomnia. Rare: Extrapyramidal symptoms, if recommended dosage is exceeded.
Fluanxol (Low Dosage) may enhance the response to alcohol and the effects of barbiturates and other CNS depressants. It should not be given concomitantly with guanethidine or similarly acting compounds, since neuroleptics may block the antihypertensive effect of these compounds. Fluanxol (Low Dosage) may lower the effect of adrenergic drugs and concomitant use of metoclopramide and piperazine increases the risk of extrapyramidal symptoms.
N05AF01 - flupentixol ; Belongs to the class of thioxanthene derivatives antipsychotics.
Tab 0.5 mg (coated) x 100's.